Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 29, 2017
Pharmacy Choice - News - Pharmaceutical Development - March 29, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

3/29/17 - AP Top Health News at 8:05 p.m. EDT
Brain and arm implants help paralyzed US man feed himself ACLU asks Ohio city to stop charging drug overdose survivors Senate, White House pass on House push to revive health bill Democratic senator asks drugmakers about opioid sales plans States push to protect birth control despite failed GOP bill FDA approves 1st drug for moderate& severe eczema
3/29/17 - AP Top Health News at 8:16 p.m. EDT
Brain and arm implants help paralyzed US man feed himself ACLU asks Ohio city to stop charging drug overdose survivors Senate, White House pass on House push to revive health bill Democratic senator asks drugmakers about opioid sales plans States push to protect birth control despite failed GOP bill FDA approves 1st drug for moderate& severe eczema
3/29/17 - British new lung cancer drug wins approval in China [Philippines News Agency]
The London stock market listed company AstraZeneca Monday announced that the China Food and Drug Administration has granted marketing authorization for its lung cancer pill Tagrisso in China. Tagrisso is designed for the treatment of adult patients with certain genetic mutations, which is the first AstraZeneca medicine approved under the CFDA's...
3/29/17 - Center Point Clinical Services' Studies Show That Pharmacist-led Interventions Increase Clinical Trial Patient Medication Adherence and Compliance and Provide Robust Study Data
Center Point Clinical Services, creator of the world's first Siteless CRO platform, announced today study results presented in two separate posters at the Academy of Managed Care Pharmacy,# AMCP2017, Managed Care and Specialty Pharmacy annual meeting in Denver, Colorado. Joe Martinez, CEO of Center Point Clinical Services and the lead author of bot
3/29/17 - Enrollment Commences in Phase III Clinical Study of Eisai's Bace Inhibitor Elenbecestat in Early Alzheimer's Disease in Japan
TOKYO, Mar 29, 2017 Eisai Co., Ltd. announced today that enrollment has commenced in Japan for MISSION AD1, a global Phase III clinical study of the in-house developed oral beta secretase cleaving enzyme inhibitor elenbecestat in patients with early Alzheimer's disease. The Phase III clinical trial program for elenbecestat consists of two global
3/29/17 - FDA Approves Genentech's OCREVUS? (Ocrelizumab) for Relapsing and Primary Progressive Forms of Multiple Sclerosis
Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration approved OCREVUS? as the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis. The FDA s approval of OCREVUS is the beginning of a new era for the MS community and represents a significant scientific a
3/29/17 - North American Health Headlines at 8:05 p.m. EDT
Senate, White House pass on House push to revive health bill States push to protect birth control despite failed GOP bill Democratic senator asks drugmakers about opioid sales plans Trumps says he expects a health care deal soon FDA approves 1st drug for moderate& severe eczema cases
3/29/17 - North American Health Headlines at 8:16 p.m. EDT
Senate, White House pass on House push to revive health bill States push to protect birth control despite failed GOP bill Democratic senator asks drugmakers about opioid sales plans Trump says he expects a health care deal soon FDA approves 1st drug for moderate& severe eczema cases
3/29/17 - Purdue Pharma Highlights Research from Multiple Studies at AMCP Managed Care & Specialty Pharma Annual Meeting 2017
Purdue Pharma L.P. announced today the presentation of results from six clinical and non-clinical research studies at the Academy of Managed Care Pharmacy Managed Care& Specialty Pharmacy Annual Meeting 2017 in Denver, Mar. 27-30, 2017. We are pleased to present results from several studies that show our commitment to the pain community while ad
3/29/17 - Regeneron Says FDA Okays New Eczema Drug Dupixent
PARIS- Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration approved DUPIXENT or dupilumab Injection, the first and only biologic medicine approved for the treatment of adults with moderate-to-severe atopic dermatitis or AD whose disease is not adequately controlled with topical prescription therapies, or.
3/28/17 - AbbVie and M2Gen Announce New Collaboration for the Oncology Research Information Exchange Network (ORIEN) Avatar Research Program
NORTH CHICAGO, Ill. and TAMPA, Fla., March 28, 2017/ PRNewswire/ AbbVie, a global biopharmaceutical company, and M2Gen, a leading health informatics solutions company, announced today that AbbVie has joined the Oncology Research Information Exchange Network Avatar Research Program. ORIEN Avatar is a collaboration between the 15 leading U.S. ca
3/28/17 - AbbVie Granted Priority Review in Japan for its Investigational Regimen of Glecaprevir/Pibrentasvir G/P for the Treatment of All Major Genotypes of...
By a News Reporter-Staff News Editor at China Weekly News- AbbVie, a global biopharmaceutical company, announced that priority review has been granted by the Japanese Ministry of Health, Labour and Welfare for its investigational, pan-genotypic, ribavirin-free regimen of glecaprevir/pibrentasvir for the treatment of all major genotypes of the chr
3/28/17 - Adamas Announces Data Presentation on ADS-5102 at the Academy of Managed Care Pharmacy 2017 Annual Meeting
Adamas Pharmaceuticals, Inc. today announced details regarding a poster presentation highlighting data from EASE LID, its Phase 3 efficacy study of ADS-5102 extended-release capsules for the treatment of levodopa-induced dyskinesia in patients with Parkinson s disease, to be presented at the Academy of Managed Care Pharmacy s 2017 Annual Me
3/28/17 - Adamas to Present at the 16th Annual Needham Healthcare Conference
Adamas Pharmaceuticals, Inc. today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, is scheduled to present at the Needham Healthcare Conference in New York on Tuesday, April 4, 2017 at 10:40 a.m. Eastern Time.. An NDA supporting ADS-5102 for the treatment of LID in patients with Parkinson s disease is und
3/28/17 - Akebia Announces Publication of Phase 2a Results for Vadadustat in Patients with Anemia Related to Chronic Kidney Disease
Akebia Therapeutics, Inc., a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor, today announced the publication of positive results from a Phase 2 a study of vadadustat, a once-daily oral HIF stabilizer in development for the treatment of anemia relat
3/28/17 - Allergan, Paratek Announce Positive Results from Two Phase 3 Trials for Moderate-to-Severe Acne Treatment [T-break Tech (Middle East)]
Allergan, a leading global pharmaceutical company and Paratek Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, announced that two Phase 3 trials of sarecycline for the treatment of moderate to severe acne met their 12 week primary efficacy...
3/28/17 - Antiva Biosciences Closes $22 Million Series C Financing
Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus infection, has raised a $22 million Series C financing led by Brace Pharma Capital with participation from new investors NS Investment, Osage University Partners and Alexandria Venture..
3/28/17 - AP Top Health News at 6:13 p.m. EDT
ACLU asks Ohio city to stop charging drug overdose survivors Senate, White House pass on House push to revive health bill Democratic senator asks drugmakers about opioid sales plans States push to protect birth control despite failed GOP bill FDA approves 1st drug for moderate& severe eczema cases Lawmakers in Republican-led Kansas vote to expand M
3/28/17 - AP Top Health News at 6:33 p.m. EDT
Brain and arm implants help paralyzed US man feed himself ACLU asks Ohio city to stop charging drug overdose survivors Senate, White House pass on House push to revive health bill Democratic senator asks drugmakers about opioid sales plans States push to protect birth control despite failed GOP bill FDA approves 1st drug for moderate& severe eczema
3/28/17 - AP Top Health News at 6:37 p.m. EDT
Brain and arm implants help paralyzed US man feed himself ACLU asks Ohio city to stop charging drug overdose survivors Senate, White House pass on House push to revive health bill Democratic senator asks drugmakers about opioid sales plans States push to protect birth control despite failed GOP bill FDA approves 1st drug for moderate& severe eczema
3/28/17 - Apexigen Receives Clinical Development Milestone Payment under Collaboration Agreement
By a News Reporter-Staff News Editor at Life Science Weekly- Apexigen, Inc., a clinical-stage biopharmaceutical company focusing on discovering and developing antibody-based therapeutics for the treatment of cancer with an emphasis on new Immuno-Oncology agents, announced the receipt of a milestone payment under a license agreement for its...
3/28/17 - Aquinox Announces Appointment of Dr. Kelvin Neu and Dr. Richard Levy to Board of Directors [National News Agency (Lebanon)]
-Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today announced that representatives from Aquinoxs largest shareholder, Baker Brothers Investments, have been appointed to the Aquinoxs board of directors.
3/28/17 - Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Development Progress
Asterias Biotherapeutics, Inc., a biotechnology company pioneering the field of regenerative medicine, today reported financial and operational results for the fourth quarter and year ended December 31, 2016 as well as recent corporate progress. In 2017, we look forward to completing study enrollment, engaging in discussions with the FDA to deter
3/28/17 - AstraZeneca Says FDA Accepts NDA For LYNPARZA Tablets
LONDON- AstraZeneca said that the US Food and Drug Administration has accepted the company's New Drug Application or NDA for LYNPARZA tablets for use in platinum-sensitive, relapsed ovarian cancer patients in the maintenance setting. The FDA has also granted priority review status with a Prescription Drug User Fee Act set for third quarter 2017.
3/28/17 - AstraZeneca Shares Progress on LYNPARZA? (olaparib) Tablets in the US
AstraZeneca today announced that the US Food and Drug Administration has accepted the company s New Drug Application for LYNPARZA? tablets for use in platinum-sensitive, relapsed ovarian cancer patients in the maintenance setting. The FDA grants Priority Review to applications for medicines that treat serious conditions and, if approved, would
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415